Filing Details
- Accession Number:
- 0001209191-18-057307
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-05 20:25:41
- Reporting Period:
- 2018-11-01
- Accepted Time:
- 2018-11-05 20:25:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1346830 | Cara Therapeutics Inc. | CARA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1597152 | Ph.d. Frederique Menzaghi | C/O Cara Therapeutics, Inc. 4 Stamford Plaza, 107 Elm St, 9Th Floor Stamford CT 06902 | Sr Vp-Research & Development | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-11-01 | 40,000 | $2.05 | 145,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-11-01 | 3,000 | $18.77 | 142,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2018-11-01 | 40,000 | $0.00 | 40,000 | $2.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2020-10-15 | No | 4 | M | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.62 to $18.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- Immediately exercisable.
Billionaire Hedge Funds
